What This Article Covers
This article summarizes published research on GHK-Cu for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.
- The supplied evidence set contains: one human/clinical study, several review articles, and multiple preclinical/mechanistic reports. Conclusions below are limited to the evidence set and its stated uncertainties.
- Reviews are used to frame mechanisms and translational hypotheses; they do not substitute for primary human outcome evidence [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
- Animal, in vitro, and biochemical findings are separated from human conclusions and should not be presented as established clinical outcomes.
Bottom Line
- Human evidence in this evidence set is narrow: one study in the context of cigarette smoke–related skeletal muscle dysfunction reports effects in that specific setting, with a proposed involvement of SIRT1; mechanistic causality in humans is not established here [pubmed:36905132].
- Broader claims about regeneration or anti‑aging are largely review‑driven and supported by preclinical models; they are hypothesis‑generating rather than confirmatory [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574].
- The evidence set does not justify dosing or generalized safety conclusions.
What Was Tested in Humans?
No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.
What Did Animal and Mechanistic Studies Show?
– Silicosis model: attenuation of lung inflammation and fibrosis with a proposed PRDX6 target [pubmed:38879894]. – Cigarette smoke–induced emphysema/inflammation: effects associated with oxidative‑stress pathways [pubmed:35936787].
– Experimental colitis: reports of beneficial effects with mechanistic exploration [pubmed:40672369].
– Attenuation of CuSO4 or LPS‑induced inflammation in larvae [pubmed:41997403].
– GHK‑Cu loaded into hydroxyapatite microspheres for localized anti‑inflammatory/antioxidant purposes in experimental systems [pubmed:40716276].
– Copper(II) binding to GHK (DFT study) [crossref:10.22144/ctu.jen.2018.052]. – Fluorescent chemosensor development based on GHK [crossref:10.1021/ol0101638; crossref:10.1002/chin.200208210]. – Stimulation of sulfated glycosaminoglycan synthesis by GHK‑Cu (biochemical context) [crossref:10.1016/0024-3205(92)90504-i].
– PubChem compound entry for GHK [pubchem:73587]. – Patent search indicating commercial interest; not efficacy evidence [patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine].
- Pulmonary models
- Gastrointestinal model
- Zebrafish inflammation model
- Biomaterials/local delivery (experimental)
- Chemistry and binding (biochemical/in vitro)
- Identity and records (ancillary)
How the Evidence Fits Together
The practical reading for GHK-Cu is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.
What Is Not Established
- Broad human efficacy for GHK-Cu is not established by this article.
- Animal, cellular, or review-level findings should not be converted into human-use claims.
- Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.
Research-Use Boundary
This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.
Selected Sources
– pubmed:36905132 — https://pubmed.ncbi.nlm.nih.gov/36905132/
- Human/clinical
– pubmed:29986520 — https://pubmed.ncbi.nlm.nih.gov/29986520/ – pubmed:35083444 — https://pubmed.ncbi.nlm.nih.gov/35083444/ – pubmed:26236730 — https://pubmed.ncbi.nlm.nih.gov/26236730/ – pubmed:39963574 — https://pubmed.ncbi.nlm.nih.gov/39963574/ – pubmed:41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/ – pubmed:41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/
- Reviews (context)
– pubmed:38879894 — https://pubmed.ncbi.nlm.nih.gov/38879894/ – pubmed:35936787 — https://pubmed.ncbi.nlm.nih.gov/35936787/ – pubmed:41997403 — https://pubmed.ncbi.nlm.nih.gov/41997403/ – pubmed:40672369 — https://pubmed.ncbi.nlm.nih.gov/40672369/ – pubmed:40716276 — https://pubmed.ncbi.nlm.nih.gov/40716276/ – crossref:10.22144/ctu.jen.2018.052 — https://doi.org/10.22144/ctu.jen.2018.052 – crossref:10.1021/ol0101638 — https://doi.org/10.1021/ol0101638 – crossref:10.1002/chin.200208210 — https://doi.org/10.1002/chin.200208210 – crossref:10.1016/0024-3205(92)90504-i — https://doi.org/10.1016/0024-3205(92)90504-i
- Preclinical/mechanistic
– pubchem:73587 — https://pubchem.ncbi.nlm.nih.gov/compound/73587 – patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine — https://patents.google.com/?q=GHK-Cu+copper+tripeptide-1+glycyl-L-histidyl-L-lysine
- Identity/records (ancillary)
Related KRL Resources
Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.
1st Time Customers Receive 10% off their 1st order over $100.00 with CODE KRL10
Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.